It is indicated for patients aged ≥2 years with obesity due to proopiomelanocortin (POMC), PCSK1, leptin receptor (LEPR) deficiencies, or Bardet-Biedl syndrome (BBS), with dosing adjusted by age and weight [24]. This evidence concerns the gene LEPR and Bardet-Biedl syndrome.